Research to take the first step to practical application of peptide vaccine therapy for oral cancer patients who can not treat

• Project/Area Number: 16K11725
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Kumamoto University
• Principal Investigator: YOSHITAKE YOSHIHIRO 熊本大学, 医学部附属病院, 非常勤診療医師 (00423682)
• Co-Investigator(Kenkyū-buntansha): 尾木 秀直 熊本大学, 大学院生命科学研究部(医), 助教 (10315426)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Project Status: Completed (Fiscal Year 2018)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 口腔がん / バイオマーカー / 免疫療法 / CTLエピトープ / 口腔癌 / ペプチドワクチン療法 / トランスレーショナルリサーチ / 口腔腫瘍 / 腫瘍免疫

Outline of Final Research Achievements

Two papers were published in the International Journal of Oncology for the purpose of searching and identifying biomarkers that can predict therapeutic effects and developing simple detection methods for them. We also found that the molecule we have published can be used as a marker to reflect the progress of oral cancer and can also be a target molecule for tumor immunotherapy. On the other hand, also regarding the purpose of establishing a more effective peptide vaccine therapy for advanced cancer patients by combining previously identified HLA class II restricted antigen peptides recognized by Th1 cells and CTL epitope peptides so far. Announced to Oncoimmunology.

Academic Significance and Societal Importance of the Research Achievements

本研究は東京大学医科学研究所および熊本大学免疫識別学講座との緊密な共同研究の成果です。本研究の結果、病期の判断マーカーもなく、また治療の効果を判定するマーカーもない口腔癌において、病状や病期を客観的に判断することのできる手段を得ることができたと考える。ニボルマブに関しても効果判定や適用患者を投与前に区分することができるかもしれない。さらに、免疫療法の治療標的分子としても、口腔癌を克服できる一筋の光明になる可能性を秘めていると考えている。

Research Products

• [Journal Article] Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer. (2018)
  • Author(s): Daigo K, Takano A, Thang PM, Yoshitake Y, Shinohara M, Tohnai I, Murakami Y, Maegawa J, Daigo Y.
  • Journal Title: Int J Oncol. Volume: 52(1) Pages: 155-165
  • DOI: 10.3892/ijo.2017.4181
  • Peer Reviewed / Open Access
• [Journal Article] 舌に発生した軟骨脂肪腫の1例 (2017)
  • Author(s): 中井大史、嶋香織、國芳秀晴、吉武義泰、竹部史朗、篠原正德
  • Journal Title: 日本口腔外科学会雑誌 Volume: 63 Pages: 21-24
  • NAID: 130005464702
  • Peer Reviewed
• [Journal Article] Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer. (2016)
  • Author(s): Thang PM, Takano A, Yoshitake Y, Shinohara M, Murakami Y, Daigo Y
  • Journal Title: Int J Oncol Volume: 49 Issue: 4 Pages: 1385-1393
  • DOI: 10.3892/ijo.2016.3649
  • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
• [Journal Article] An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs (2016)
  • Author(s): M. Hirayama, Y. Tomita, A. Yuno, H. Tsukamoto, S. Sejju, Y. Imamura, M. A. Sayem, A. Irie, Y. Yoshitake, D. Fukuma, M. Shinohara, A. Hamada, H. Jono, E. Yuba, K. Kono, K. Yoshida, T. Tsunoda, H. Nakayama, Y. Nishimura
  • Journal Title: OncoImmunology Volume: 5 Issue: 6 Pages: e1123368-e1123368
  • DOI: 10.1080/2162402x.2015.1123368
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Sentinel lymph node biopsy reduces the incidence of secondary neck metastasis in patients with oral squamous cell carcinoma. (2016)
  • Author(s): Hiraki A, Fukuma D, Nagata M, Shiraishi S, Kawahara K, Matsuoka Y, Nakagawa Y, Yoshida R, Tanaka T, Yohitake Y, Shinohara M, Yamashita Y, Nakayama H.
  • Journal Title: Molecular and Clinical Oncology Volume: 5 Issue: 1 Pages: 57-60
  • DOI: 10.3892/mco.2016.882
  • Peer Reviewed
• [Journal Article] S-1併用化学放射線療法中の口腔癌患者に生じた重篤な薬剤性腸炎の1例 (2016)
  • Author(s): 田中 拓也, 尾木 秀直, 吉武 義泰, 太田 和俊, 篠原 正德, 中山 秀樹
  • Journal Title: 日本口腔外科学会雑誌 Volume: 62 Pages: 352-357
  • NAID: 130005416109
  • Peer Reviewed
• [Presentation] Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS. (2017)
  • Author(s): ③Yoshihiro Yoshitake, Daiki Fukuma, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Takuya Tanaka, Masashi Nagata, Kenta Kawahara, Yoshihiro Nakagawa, Ryoji Yoshida, Hidenao Ogi, Akimitsu Hiraki, Hirofumi Jono, Akinobu Hamada, Koji Yoshida, Takuya Tsunoda, Yasuharu Nishimura, Yusuke Nakamura, Masanori Shinohara
  • Organizer: European Society for Medical Oncology （ESMO）
  • Int'l Joint Research